Distribution Agreement for GMP Compliant hESC Lines, BioTime (AMEX:BTX)
BTX and the CIRM are to make 5 clinical-grade human embryonic stem (hES) cell lines available to California researchers.
California Institute for Regenerative Medicine (CIRM) is the stem cell agency created when California voters supported a $3B funding measure for stem cell-related research and clinical translation;
- Under the agreement, BTX will initially provide research grade cell lines and within 1 year, BTX will also make available GMP-grade cell lines along with certain documentation and complete DNA sequence information;
- The parties anticipate that the use of the GMP grade cell lines may streamline the translation of basic science to human therapies. Should the users of the cell lines and BTX eventually sign definitive license agreements for commercial use of the cell lines, BTX will receive a royalty on net sales.
Categories: AMEX: BTX, New Distribution Agreement, Stem Cell Technology
